Year: 2021
Type: review
Abstract: Mesothelioma is an aggressive cancer that is associated with exposure to asbestos. Although asbestos is banned in several countries, including the UK, an epidemic of mesothelioma is predicted to affect middle-income countries during this century owing to their heavy consumption of asbestos. The prognosis for patients with mesothelioma is poor, reflecting a failure of conventional chemotherapy that has ultimately resulted from an inadequate understanding of its biology. However, recent work has revolutionised the study of mesothelioma, identifying genetic and pathophysiological vulnerabilities, including the loss of tumour suppressors, epigenetic dysregulation and susceptibility to nutrient stress. We discuss how this knowledge, combined with advances in immunotherapy, is enabling the development of novel targeted therapies.
Source: British Journal of Cancer
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,480
Funders: June Hancock Mesothelioma Research Fund, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Royal Society, British Lung Foundation, Rosetrees Trust, China Scholarship Council, UK Regenerative Medicine Platform, Medical Research Council, Engineering and Physical Sciences Research Council, NIHR Cambridge Biomedical Research Centre, Division of Materials Research
Awards: G139696651, G1804826484, UKRMP Hub: The Engineered Cell Environment., G2733156708, G299057155, G3584577881, G370598735, Targeting PPP1R15 in malignancy, G4829443020, G6077662935, G6331222924, EPSRC IRC in Targeted Delivery for Hard-to-Treat Cancers, Mobilising epithelial stem cells for human lung regeneration, Effects of alpha1-antitrypsin polymerisation on organelle structure and fluidity in hepatocytes
OpenAlex ID: W3182664105
